Leprosy Training Module for Medical Officers

More documents

Recommendations

Info

PB MDT ( Adult ) : Supervised dose on day 1 Rifampicin Dapsone 600 mg 100 mg Unsupervised dose : Dapsone 100 mg daily for 27 days MB MDT ( Adult ) Supervised dose on day 1 Rifampicin 600 mg Clofazimine 300 mg Dapsone 100 mg Unsupervised dose : Clofazimine 50 mg daily Dapsone 100 mg daily , both for 27 days 43
PB MDT ( Child 10 –14 yrs. ) : Supervised dose on day 1 Rifampicin Dapsone 450 mg 50 mg Unsupervised dose : Dapsone 50mg daily for 27 days MB MDT ( Child 10 –14 yrs. ) : Supervised dose on day 1 Rifampicin 450 mg Clofazimine 150 mg Dapsone 50 mg Unsupervised dose : for 27 days Clofazimine 50 mg on alternate days Dapsone 50 mg daily 44
Page 1 and 2: NLEP Leprosy Training Module for Me
Page 3 and 4: Task of Medical Officers for NLEP (
Page 5 and 6: The Disease - Leprosy Leprosy is a
Page 7 and 8: Epidemiology
Page 9 and 10: 30 25 25.9 Prevalence Rate of Lepro
Page 11 and 12: Spread of Leprosy Source of Infecti
Page 13 and 14: Diagnosis & Clinical Examination
Page 15 and 16: of these signs, nerve thickening by
Page 17 and 18: ( B ) Skin Examination : Remember t
Page 19 and 20: Method for testing anaesthesia : Fi
Page 21 and 22: • Look at the patient’s face wh
Page 23 and 24: 2. Assessment of Nerve Function : N
Page 25 and 26: VMT - Radial Nerve Ask the patient
Page 27 and 28: ST - Sensory Test - Hand Ulnar Medi
Page 29 and 30: Classification of Leprosy
Page 31 and 32: Examples showing WHO classification
Page 33 and 34: PB Leprosy PB Leprosy : Small Solit
Page 35 and 36: PB Leprosy : • Rounded lesion wit
Page 37 and 38: MB Leprosy : • One of many patche
Page 39 and 40: MB Leprosy : • Several Punched ou
Page 41 and 42: MB Leprosy : • Thick erythematous
Page 43 and 44: MB Leprosy : • Extensive • Symm
Page 45 and 46: MB Leprosy : • Marked Diffused In
Page 47 and 48: Treatment for Leprosy MDT Drugs : T
Page 49: Advantages of MDT MDT kills the
Page 53 and 54: Reactions in Leprosy
Page 55 and 56: Patients with following characteris
Page 57 and 58: Type I Lepra Reactions Type I Lepra
Page 59 and 60: Type I Lepra Reaction • Inflammat
Page 61 and 62: Type II Lepra Reaction • ENL nodu
Page 63 and 64: Difference between Type I Lepra Rea
Page 65 and 66: Corticosteroid Therapy : • Cortic
Page 67 and 68: Disabilities in Leprosy
Page 69 and 70: The two most important measures for
Page 71 and 72: Primary Disability Primary Disabili
Page 73 and 74: Ulnar Claw • Clawing of little an
Page 75 and 76: Secondary Disability Primary disabi
Page 77 and 78: Prevention of Disabilities ( POD )
Page 79 and 80: Three Levels of Interventions for P
Page 81 and 82: Care of Primary Disability to preve
Page 83 and 84: Loss of Sensation in Hands & Feet (
Page 85 and 86: Care of wounds - Simple Wounds If t
Page 87 and 88: Exercises for Paralysis / Weakness
Page 89 and 90: Exercises for Lateral Popliteal ner
Page 91 and 92: Eye care 2 Corneal Anaesthesia Pati
Page 93 and 94: Elimination of Leprosy It is well k
Page 95 and 96: Integration Why integration is esse
Page 97: Simplified Information System ( SIS
Page 100 and 101:
2. Treatment Record ( L. F. 02 )
Page 102 and 103:
Treatment Record to be attached her
Page 104 and 105:
Reports The simplified information
Page 106 and 107:
3. Child proportion among new cases
Page 108:
National Leprosy Eradication Progra
show all

Leprosy Training Module for Medical Officers

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?